FY2022 Earnings Forecast for AstraZeneca plc Issued By Leerink Swann (NYSE:AZN)


FY2022 Earnings Forecast for AstraZeneca plc Issued By Leerink Swann (NYSE:AZN)

The stock of AstraZeneca PLC (LON:AZN) earned "Hold" rating by Jefferies on Thursday, June 30. Citigroup upgraded AstraZeneca to a buy rating in a report on Wednesday, October 18th. Finally, Zacks Investment Research upgraded AstraZeneca from a "sell" rating to a "hold" rating in a research report on Monday, January 22nd. HSBC Holdings plc downgraded shares of AstraZeneca plc to a reduce rating and set a GBX 4,500 ($60.67) price target for the company.in a research report on Tuesday, July 4th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. The stock presently has an average rating of Hold and a consensus target price of GBX 5,041.09 ($67.97).

AstraZeneca (AZN) traded down GBX 75 ($1.05) during trading on Friday, reaching GBX 4,770 ($66.88). 8,800,000 shares of the company's stock were exchanged, compared to its average volume of 4,510,000. AstraZeneca has a 12-month low of GBX 4,260 ($59.73) and a 12-month high of GBX 5,520 ($77.40). The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.72. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since February 11, 2017 and is uptrending. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.44 by $0.86. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. The firm had revenue of $5.78 billion during the quarter, compared to analyst estimates of $5.49 billion. During the same period in the previous year, the company posted $1.21 EPS. research analysts forecast that AstraZeneca will post 1.67 earnings per share for the current fiscal year.

The firm also recently disclosed a dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be paid a dividend of $0.95 per share. This represents a yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th. AstraZeneca's dividend payout ratio is 116.10%.

Institutional investors have recently added to or reduced their stakes in the company. FDx Advisors Inc. increased its holdings in shares of AstraZeneca by 8.8% in the fourth quarter. First Republic Investment Management Inc. now owns 55,825 shares of the company's stock valued at $1,938,000 after acquiring an additional 6,909 shares during the last quarter. Valeo Financial Advisors LLC acquired a new stake in AstraZeneca in the third quarter valued at $133,000. Wealthcare Advisory Partners LLC acquired a new stake in AstraZeneca in the third quarter valued at $184,000. UBS Group set a GBX 4,550 ($63.80) target price on shares of AstraZeneca and gave the company a neutral rating in a research report on Monday, January 8th. Institutional investors and hedge funds own 14.79% of the company's stock. Natixis Asset Management who had been investing in Bce Inc. for a number of months, seems to be bullish on the $39.52 billion market cap company. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & global trademark and copyright laws.

Becker Capital Management Inc increased its stake in Astrazeneca Plc (AZN) by 7.21% based on its latest 2017Q3 regulatory filing with the SEC. The Company's marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases.